Paola Costa-Mallen1, Cyrus P Zabetian2, Pinky Agarwal3, Shu-Ching Hu4, Dora Yearout5, Ali Samii2, James B Leverenz6, John W Roberts7, Harvey Checkoway8. 1. Bastyr University Research Institute, Kenmore, WA, USA. Electronic address: pcostamallen@bastyr.edu. 2. Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA; Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA. 3. Booth Gardner Parkinson's Care Center, Evergreen Health, Kirkland, WA, USA. 4. Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA. 5. Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA. 6. Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. 7. Virginia Mason Medical Center, Seattle, WA, USA. 8. University of California San Diego, Department of Family & Preventive Medicine, La Jolla, USA.
Abstract
INTRODUCTION: Haptoglobin is a hemoglobin-binding protein that exists in three functionally different phenotypes, and haptoglobin phenotype 2-1 has previously been associated with Parkinson disease (PD) risk, with mechanisms not elucidated. Some evidence is emerging that low levels of serum iron may increase PD risk. In this study we investigated whether PD patients have lower serum iron and ferritin than controls, and whether this is dependent on haptoglobin phenotype. We also investigated the effect of Hp phenotype as a modifier of the effect of smoking on PD risk. METHODS: The study population consisted of 128 PD patients and 226 controls. Serum iron, ferritin, and haptoglobin phenotype were determined, and compared between PD cases and controls. Stratified analysis by haptoglobin phenotype was performed to determine effect of haptoglobin phenotype on serum iron parameter differences between PD cases and controls and to investigate its role in the protective effect of smoking on PD risk. RESULTS: PD cases had lower serum iron than controls (83.28 ug/100 ml vs 94.00 ug/100 ml, p 0.006), and in particular among subjects with phenotype 2-1. The protective effect of smoking on PD risk resulted stronger in subjects with phenotype 1-1 and 2-2, and weakest among subjects with phenotype 2-1. Ferritin levels were higher in PD cases than controls among subjects of White ethnicity. CONCLUSIONS: Our results report for the first time that the haptoglobin phenotype may be a contributor of iron levels abnormalities in PD patients. The mechanisms for these haptoglobin-phenotype specific effects will have to be further elucidated.
INTRODUCTION:Haptoglobin is a hemoglobin-binding protein that exists in three functionally different phenotypes, and haptoglobin phenotype 2-1 has previously been associated with Parkinson disease (PD) risk, with mechanisms not elucidated. Some evidence is emerging that low levels of serum iron may increase PD risk. In this study we investigated whether PDpatients have lower serum iron and ferritin than controls, and whether this is dependent on haptoglobin phenotype. We also investigated the effect of Hp phenotype as a modifier of the effect of smoking on PD risk. METHODS: The study population consisted of 128 PDpatients and 226 controls. Serum iron, ferritin, and haptoglobin phenotype were determined, and compared between PD cases and controls. Stratified analysis by haptoglobin phenotype was performed to determine effect of haptoglobin phenotype on serum iron parameter differences between PD cases and controls and to investigate its role in the protective effect of smoking on PD risk. RESULTS:PD cases had lower serum iron than controls (83.28 ug/100 ml vs 94.00 ug/100 ml, p 0.006), and in particular among subjects with phenotype 2-1. The protective effect of smoking on PD risk resulted stronger in subjects with phenotype 1-1 and 2-2, and weakest among subjects with phenotype 2-1. Ferritin levels were higher in PD cases than controls among subjects of White ethnicity. CONCLUSIONS: Our results report for the first time that the haptoglobin phenotype may be a contributor of iron levels abnormalities in PDpatients. The mechanisms for these haptoglobin-phenotype specific effects will have to be further elucidated.
Authors: M R Langlois; M E Martin; J R Boelaert; C Beaumont; Y E Taes; M L De Buyzere; D R Bernard; H M Neels; J R Delanghe Journal: Clin Chem Date: 2000-10 Impact factor: 8.327
Authors: Daniela Berg; Wolfgang Roggendorf; Ute Schröder; Rüdiger Klein; Thomas Tatschner; Peter Benz; Oliver Tucha; Michael Preier; Klaus W Lange; Karlheinz Reiners; Manfred Gerlach; Georg Becker Journal: Arch Neurol Date: 2002-06
Authors: Paola Costa-Mallen; Cyrus P Zabetian; Pinky Agarwal; Shu-Ching Hu; Dora Yearout; Ali Samii; James B Leverenz; John W Roberts; Harvey Checkoway Journal: Parkinsonism Relat Disord Date: 2016-01 Impact factor: 4.891
Authors: Alex Lewin; Shea Hamilton; Aviva Witkover; Paul Langford; Richard Nicholas; Jeremy Chataway; Charles R M Bangham Journal: Wellcome Open Res Date: 2016-11-15
Authors: Freya Shephard; Oliver Greville-Heygate; Susan Liddell; Richard Emes; Lisa Chakrabarti Journal: Mitochondrion Date: 2016-05-12 Impact factor: 4.160